Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
J Formos Med Assoc ; 121(11): 2360-2364, 2022 Nov.
Article in English | MEDLINE | ID: covidwho-2121333

ABSTRACT

In Taiwan, 14,308 locally acquired COVID-19 cases among customers and employees in Sexy Tea shops were the first cases from May 9-August 28, 2021 (weeks 19-34). Nine weeks after the community spread of COVID-19 began, the proportion of people living with HIV (PLHIV) among the COVID-19 patients peaked at 35.7%, affecting 192 HIV patients, while the prevalence of HIV infection was 0.15%. In addition to a nationwide Level 3 epidemic alert, the Taiwan Centers for Disease Control (Taiwan CDC) launched four strategies to contain this outbreak among PLHIV in this prevaccine era, including improving the quality of contact tracing, delivering health information via peer navigators, expanding SARS-CoV-2 screening and encouraging vaccination, and addressing hesitancy. The outbreak of COVID-19 related to Alpha strain among PLHIV in 2021 ceased four weeks after peaking and lasted eight weeks.


Subject(s)
COVID-19 , HIV Infections , COVID-19/epidemiology , Disease Outbreaks/prevention & control , HIV Infections/complications , HIV Infections/epidemiology , Humans , SARS-CoV-2 , Taiwan/epidemiology , Tea
2.
Transplant Proc ; 54(6): 1575-1578, 2022.
Article in English | MEDLINE | ID: covidwho-1487992

ABSTRACT

We report a case of a heart transplant recipient who presented with a rapidly growing Epstein-Barr virus (EBV)-positive, diffuse large B-cell lymphoma 7 days after receiving the first dose of the ChAdOx1 nCoV-19 vaccine. Because of the atypical radiologic presentation, the initial tentative diagnosis was a mediastinal abscess. This observation indicates a potential risk of EBV reactivation after coronavirus disease 2019 (COVID-19) vaccination, which might lead to or aggravate the presentation of posttransplant lymphoproliferative disorder in transplantation patients. Transplant surgeons should be aware of the potential immunomodulatory effects of the COVID-19 vaccination.


Subject(s)
COVID-19 , ChAdOx1 nCoV-19 , Epstein-Barr Virus Infections , Heart Transplantation , Lymphoproliferative Disorders , Humans , ChAdOx1 nCoV-19/adverse effects , COVID-19/prevention & control , Epstein-Barr Virus Infections/complications , Epstein-Barr Virus Infections/diagnosis , Herpesvirus 4, Human , Lymphoproliferative Disorders/chemically induced , Lymphoproliferative Disorders/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL